Research objective
Nano-Supremi aims to uncover and exploit novel physical, chemical and biological properties of bio-nanodevices that can be utilised at the micro- and macro-scale for the mastering of intelligent materials and new diagnostic tools.
Zooming on intracellular trafficking of nanomedicines and biomolecules: We are applying super-resolution and advanced microscopy techniques (SIM, STORM, STED, FLIM, FCS) to quantitatively and reliably assess the size, shape, intracellular trafficking, targeting and efficacy of newly developed nanomedicines and DNA molecular switches. This will ultimately result in the evaluation of in vitro protein activity and therapeutic efficacy of nanomedicines, filling the gap between innovative research and its exploitation in clinical setting.
Three case studies were set up to investigate nanoscale synthetic and biological structures and to probe nanoscale dynamic processes.
1- Intracellular targeting and monitoring of Transcription Factor proteins (NF-kB and TEAD) in living cells.
2- Intracellular and quantitative detection of shuttling proteins (YAP/TAZ) in living cells.
3- Intracellular trafficking of siRNA based nanomedicines to downregulate YAP protein.
Training objective:
We are providing young scientists, post-doctoral researchers and academic staff, with cross-disciplinary training in molecular biology, optics, bio-imaging, nano-biomaterials, bioanalytical chemistry. Nano-Supremi programme promotes a transfer of knowledge by experimental training, joint workshops and seminars, between research and educational institutions located in Italy, Australia, Czech Republic, Unites States, Cuba and Brazil.
IMPACT ON SOCIETY
The challenges for personalizing healthcare represent an important priority within European policies. In particular, RNA and DNA-based therapeutics have rapidly advanced from research discovery to preclinical and clinical trials. One of the primary challenges associated with cancer therapy is delivering the therapeutic agent to the tumour in a safe and effective manner. Given their peculiar behaviour and function within the cell, it is overseen that the targets protein chosen (Nf-kB, NFAT, YAP/TEAD) in this project will be used as diagnostic markers for pathologies like cancer and cardiovascular diseases.
Nano-Supremi is developing bio-imaging methods to non-invasively visualise biological processes, triggered by nanomaterials, in real time, for therapy (cancer therapy, regenerative medicine) and diagnostics.
The development of innovative therapeutic and diagnostic products and technologies could boost growth, and the economic impact of biotechnology, pharmaceutical, optics companies, especially SMEs, dealing with the manufacturing of drug-delivery platforms. This is a niche where Europe can gain prestige and a corresponding share of the global market for bio-nanomaterials.